Novo Holdings co-leads £90 million ($114 million) Series A financing for Myricx Bio to advance a novel payload class for antibody-drug conjugates
- Funds will be used to build out Myricx Bio’s proprietary payload platform and advance its pipeline through clinical proof of concept
- Novo Holdings Venture Investments Partner Michael Bauer will join Myricx Board of Directors and Principal Max Klement will join Myricx Board as an Observer
- This is the largest European biotech Series A financing this year
Copenhagen, Denmark, 8 July 2024 – Novo Holdings, a leading life science investor, today announces that it has co-led a £90 million ($114 million) Series A financing for Myricx Bio (‘Myricx’), the largest European biotech Series A financing this year. Myricx Bio is a UK biotech company focusing on the discovery and development of a novel payload class for antibody-drug conjugates (ADCs).
